Logo Image
Back

Updates in Immunotherapy for Non–Small Cell Lung Cancer

Updates in Immunotherapy for Non–Small Cell Lung Cancer

The latest research and impact of recent clinical trials on treatment selection using immunotherapy-based regimens for metastatic non–small cell lung cancer (NSCLC), consolidation immunotherapy in stage III disease, and perioperative regimens with immunotherapy in resectable NSCLC.

Updates in Immunotherapy for Non–Small Cell Lung Cancer

Episodes

All
All

EP. 1: Frontline Treatment of PD-L1+ Stage IV NSCLC: Cemiplimab

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.

EP. 2: Frontline I-O Monotherapy Versus Combination Therapy for PD-L1+ Stage IV NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

EP. 3: Frontline Treatment of Stage IV NSCLC: IPI/NIVO

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Neal Edward Ready, MD, PhD, describes which patients with stage IV non–small cell lung cancer may benefit from the combination of ipilimumab and nivolumab in the frontline treatment setting.

EP. 4: Frontline Treatment Decisions for Stage IV NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Considerations for selecting frontline therapy for metastatic non–small cell lung cancer based on various new data and treatment approvals in the field of immunotherapy.

EP. 5: Frontline Treatment of Stage IV NSCLC: Biomarkers

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Martin Dietrich, MD, PhD, shares his thoughts on PD-L1 status, tumor mutational burden, and other predictive and prognostic biomarkers when making treatment decisions for patients with stage IV non–small cell lung cancer.

EP. 9: Durvalumab for Unresectable Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.

EP. 10: Risks of Pneumonitis in Unresectable Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.

EP. 11: Appropriateness for Durvalumab in Unresectable Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Variables that influence patient selection for durvalumab consolidation after CRT as part of treatment for unresectable stage III non–small cell lung cancer.

EP. 12: CRT and I-O for Unresectable Stage III NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy S. Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

EP. 13: Neoadjuvant Immunotherapy for Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

EP. 14: Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Neal Edward Ready, MD, PhD, Duke Medical Center,Sandip P. Patel, MD, University of California San Diego

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

EP. 15: Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

EP. 16: Biomarkers for Immunotherapy in Resectable NSCLC

ByMark A. Socinski, MD, AdventHealth Cancer Institute,Martin Dietrich, MD, PhD,Roy Herbst, MD, PhD, Yale Cancer Center,Chaitali Nangia, MD, Patty and George Hoag Cancer Center,Sandip P. Patel, MD, University of California San Diego,Neal Edward Ready, MD, PhD, Duke Medical Center

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.